Aflac stock holds around $117 as insider selling meets steady earnings outlook
Published on 08/29/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Aflac Inc. (US0010551028) stock is trading just under $117 as of August 28, 2026, with recent insider transactions drawing attention to the insurer's valuation and income profile.
Insider moves and current market pricing
Recent filings show that a major shareholder related to Japan Post Holdings Co., Ltd. has reduced its stake in Aflac, selling shares that form part of a position now reported at 50,752,390 common shares. Investing.com coverage of Japan Post Holdings transactions notes that Aflac currently trades at $116.94, giving the company a market capitalization of $58.45 billion and a price-to-earnings ratio of 12.44 as of August 28, 2026.
Market data from a real-time quote page shows Aflac stock changing hands intraday near this level, with a quote of $116.83 at 1:58 p.m. ET on August 28, 2026. AFL real-time stock quote page indicates that the price at that time reflected a decline of $0.62, or 0.53 percent, on the session, underscoring that the shares are trading slightly below the average analyst target.
Analyst view and 2026 earnings expectations
Recent analyst data compiled in a broker overview puts Aflac's consensus rating at Hold, with an average price target of $116.62. MarketBeat overview of Aflac rating and targets states that two analysts currently rate the shares Strong Buy, two rate them Buy, seven assign a Hold rating, and three rate them Sell, reflecting a mixed but overall neutral stance.
The same analyst compilation expects Aflac to post earnings per share of 7.04 for the current fiscal year, highlighting a valuation that is aligned with this forecast and the company’s moderate price-to-earnings multiple near 12.5 as referenced in recent commentary. With the stock trading at $116.66 at the latest referenced opening level, the market is pricing the shares close to 16.6 times the expected 2026 EPS, while the stated price-to-earnings ratio near 12.44 reflects trailing results and suggests some upside if the forecast is met.
For investors, the alignment between the $116.62 average target price and the prevailing trading band around $116.50 to $116.94 indicates limited implied upside in the consensus view, but reinforces the perception of Aflac as a steady income-oriented holding backed by ongoing dividend payments.
Institutional flows and defensive profile
Institutional investors continue to adjust their positions in Aflac, with recent filings showing both purchases and sales of the stock. One institutional holder disclosed an opening level around $116.66 for Aflac on the most recent trading day, underscoring that professional investors are transacting at levels broadly consistent with the consensus valuation range. MarketBeat summary of recent institutional activity in Aflac also highlights that the company’s dividend policy remains an important support for income-focused strategies.
At a market capitalization of $58.45 billion and with a trailing price-to-earnings ratio reported at 12.44, Aflac stands out as a defensive financial stock that combines scale with relatively moderate valuation. Investing.com data on Aflac valuation metrics shows that the P/E multiple is comfortably below the levels often seen in higher-growth sectors, pointing to a focus on stability and cash return rather than rapid expansion.
Analyst commentary referenced in the institutional overview characterizes Aflac's dividend growth strategy as a solid defensive approach, and this positioning helps explain why institutional buying can coexist with significant insider selling. For retail investors, the combination of a Hold-rated consensus, a price level near the average target, and ongoing dividend support suggests that future performance will depend heavily on the company’s ability to meet or exceed the 7.04 EPS forecast for the year.
Supplemental insurance products remain core to the story
Aflac Inc. focuses on supplemental insurance products that are designed to help policyholders cover out-of-pocket health care and living expenses alongside primary coverage. Company profile summary highlighting Aflac business focus describes the business as providing policies that offer cash benefits when policyholders face medical events, enabling them to manage deductibles, co-payments, and everyday bills while dealing with treatment.
This product focus has historically supported resilient earnings and cash flow even in periods of economic uncertainty, because supplemental coverage often complements employer or government health plans rather than competing directly with them. As the company pursues its dividend growth strategy and sustains a moderate valuation, the underlying demand for these products remains a fundamental driver of its ability to deliver the expected 7.04 EPS in the current fiscal year.
Aflac stock price context
As of August 28, 2026, Aflac stock is quoted between $116.52 and $116.94 on recent data snapshots, with a real-time quote of $116.83 at 1:58 p.m. ET signaling a modest 0.53 percent decline on that session. Latest intraday pricing for AFL and Market overview page listing AFL quote data both place the shares in this tight band, consistent with the stated average target price of $116.62 and the broader picture of a defensive, income-oriented stock trading close to its consensus fair value.
For US retail investors, the key numerical signals are therefore a current price just under $117 as of August 28, 2026, a trailing price-to-earnings ratio of 12.44, a market capitalization of $58.45 billion, and an earnings forecast of 7.04 per share for the ongoing fiscal year. Together, these figures suggest that Aflac offers exposure to a large, established insurer where valuation, dividends, and incremental earnings growth are more central than rapid price appreciation.
